IRIS

Chlordane (Technical)

CASRN 12789-03-6

Health Hazard Assessments for Effects Other than Cancer

Reference Dose for Oral Exposure (RfD) (PDF) (46 pp, 262 K) last updated: 02/07/1998

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Hepatic 5 x 10-4 Hepatic necrosis NOAEL : 1.5 x 10-1
mg/kg-day
300 Medium

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (46 pp, 262 K) last updated: 02/07/1998

System RfC (mg/m3) Basis PoD Composite UF Confidence
Hepatic 7 x 10-4 Hepatic effects NOAEL (HEC): 6.5 x 10-1
mg/m3
1000 Low

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (46 pp, 262 K) last updated: 02/07/1998

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Known/likely human carcinogen Proposed Guidelines for Carcinogen Risk Assessment (US EPA, 1996)
Basis:
  • Under the 1996 Proposed Guidelines, chlordane would be characterized as a likely carcinogen by all routes of exposure.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (46 pp, 262 K)

Oral Slope Factor: 3.5 x10 -1 per mg/kg-day
Drinking Water Unit Risk: 1 x10 -5 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma (IRDC, 1973; NCI, 1977; Khasawinah and Grutsch, 1989b)



Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (46 pp, 262 K)

Inhalation Unit Risk: 1 x10 -4 per µg/m3
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma (IRDC, 1973; NCI, 1977; Khasawinah and Grutsch, 1989b)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.